SNP selection at the NAT2 locus for an accurate prediction of the acetylation phenotype

Genetics in Medicine

Volumn 8, Issue 2, 2006, Pages 76-85

  Sabbagh, Audrey ^a,b   Darlu, Pierre ^a  

^a INSERM   (France)

^b HÔPITAL PAUL BROUSSE   (France)

Author keywords

Acetylation polymorphism; Classification methods; Clinical pharmacy; Genotyping tests; SNP selection

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; DNA MARKER; NAT2 PROTEIN, HUMAN;

ACETYLATOR PHENOTYPE; ARTICLE; ARTIFICIAL NEURAL NETWORK; CLASSIFICATION TREE; COST EFFECTIVENESS ANALYSIS; DECISION THEORY; DRUG ACETYLATION; DRUG DETERMINATION; DRUG EFFICACY; GENE; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC DIFFERENCE; GENETIC MARKER; HUMAN; INTERMETHOD COMPARISON; MULTIFACTOR DIMENSIONALITY REDUCTION; NAT2 GENE; PHARMACOGENETICS; PREDICTOR VARIABLE; RACE; SINGLE NUCLEOTIDE POLYMORPHISM; TIME; ACETYLATION; DNA SEQUENCE; ETHNIC GROUP; FEASIBILITY STUDY; GENETICS; PHENOTYPE; PHYLOGENY;

ACETYLATION; ARYLAMINE N-ACETYLTRANSFERASE; ETHNIC GROUPS; FEASIBILITY STUDIES; GENES, MDR; HUMANS; NEURAL NETWORKS (COMPUTER); PHENOTYPE; PHYLOGENY; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA;

EID: 33645392027     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gim.0000200951.54346.d6     Document Type: Article

References (53)

1. Hein DW, McQueen CA, Grant DM, Goodfellow GH, et al. Pharmacogenetics of the arylamine N-acetyltransferases: a symposium in honor of Wendell W. Weber. Drug Metab Dispos 2000;28:1425-1432.
2. Blum M, Grant DM, McBride W, Heim M, et al. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol 1990;9:193-203.
3. Ohsako S, Deguchi T. Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver. J Biol Chem 1990;265:4630-4634.
4. Blum M, Demierre A, Grant DM, Heim M, et al. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci U S A 1991;88:5237-5241.
5. Grant DM, Hughes NC, Janezic SA, Goodfellow GH, et al. Human acetyltransferase polymorphisms. Mutat Res 1997;376:61-70.
6. Upton A, Johnson N, Sandy J, Sim E. Arylamine N-acetyltransferases - of mice, men and microorganisms. Trends Pharmacol Sci 2001;22:140-146.
7. Butcher NJ, Boukouvala S, Sim E, Minchin RF. Pharmacogenetics of the arylamine N-acetyltransferases. Pharmacogenomics J 2002;2:30-42.
8. Meisel P. Arylamine N-acetyltransferases and drug response. Pharmacogenomics 2002;3:349-366.
9. Hiratsuka M, Kishikawa Y, Takekuma Y, Matsuura N, et al. Genotyping of the N-acetyltransferase 2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients. Drug Metab Pharmacokinet 2002;17:357-362.
10. Tanaka E, Taniguchi A, Urano W, Nakajima H, et al. Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. J Rheumatol 2002;29:2492-2499.
11. Parkin DP, Vandenplas S, Botha FJ, Vandenplas ML, et al. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med 1997;155:1717-1722.
12. Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, Scheidel B, et al. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother 2005;49:1733-1738.
13. Tang BK, Kadar D, Qian L, Iriah J, et al. Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clin Pharmacol Ther 1991;49:648-657.
14. Vincent-Viry M, Pontes ZB, Gueguen R, Galteau MM, et al. Segregation analyses of four urinary caffeine metabolite ratios implicated in the determination of human acetylation phenotypes. Genet Epidemiol 1994;11:115-129.
15. Mrozikiewicz PM, Cascorbi I, Brockmoller J, Roots I. Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase gene in the Polish population. Clin Pharmacol Ther 1996;59:376-382.
16. Meisel P, Schroeder C, Wulff K, Siegmund W. Relationship between human genotype and phenotype of N-acetyltransferase (NAT2) as estimated by discriminant analysis and multiple linear regression:1. Genotype and N-acetylation in vivo. Pharmacogenetics 1997;7:241-246.
17. Gross M, Kruisselbrink T, Anderson K, Land N, et al. Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population. Cancer Epidemiol Biomarkers Prev 1999;8:683-692.
18. Jorge-Nebert LF, Eichelbaum M, Griese EU, Inaba T, et al. Analysis of six SNPs of NAT2 in Ngawbe and Embera Amerindians of Panama and determination of the Embera acetylation phenotype using caffeine. Pharmacogenetics 2002;12:39-48.
19. Lee SY, Lee KA, Ki CS, Kwon OJ, et al. Complete sequencing of a genetic polymorphism in NAT2 in the Korean population. Clin Chem 2002;48:775-777.
20. Agundez JA, Olivera M, Martinez C, Ladero JM, et al. Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white population. Pharmacogenetics 1996;6:423-428.
21. Xu CF, Lewis K, Cantone KL, Khan P, et al. Effectiveness of computational methods in haplotype prediction. Hum Genet 2002;110:148-156.
22. Sabbagh A, Darlu P. Inferring haplotypes at the NAT2 locus: the computational approach. BMC Genet 2005;6:30.
23. Zhang K, Calabrese P, Nordborg M, Sun F, et al. Haplotype block structure and its applications to association studies: power and study designs. Am J Hum Genet 2002;71:1386-1394.
24. Zhang H, Bonney G. Use of classification trees for association studies. Genet Epidemiol 2000;19:323-332.
25. North BV, Curtis D, Cassell PG, Hitman GA, et al. Assessing optimal neural network architecture for identifying disease-associated multi-marker genotypes using a permutation test, and application to calpain 10 polymorphisms associated with diabetes. Ann Hum Genet 2003;67:348-356.
26. Ritchie MD, Hahn LW, Roodi N, Bailey LR, et al. Multifactor- dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 2001;69:138-147.
27. Agundez JA, Olivera M, Ladero JM, Rodriguez-Lescure A, et al. Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers. Pharmacogenetics 1996;6:501-512.
28. Martinez C, Agundez JA, Olivera M, Llerena A, et al. Influence of genetic admixture on polymorphisms of drug-metabolizing enzymes: analyses of mutations on NAT2 and C gamma P2E1 genes in a mixed Hispanic population. Clin Pharmacol Ther 1998;63:623-628.
29. Loktionov A, Moore W, Spencer SP, Vorster H, et al. Differences in N-acetylation genotypes between Caucasians and Black South Africans: implications for cancer prevention. Cancer Detect Prev 2002;26:15-22.
30. Cascorbi I, Drakoulis N, Brockmoller J, Maurer A, et al. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995;57:581-592.
31. Aynacioglu AS, Cascorbi I, Mrozikiewicz PM, Roots I. Arylamine N-acetyltransferase (NAT2) genotypes in a Turkish population. Pharmacogenetics 1997;7:327-331.
32. Deloménie C, Sica L, Grant DM, Krishnamoorthy R, et al. Genotyping of the polymorphic N-acetyltransferase (NAT2*) gene locus in two native African populations. Pharmacogenetics 1996;6:177-185.
33. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003;73:1162-1169.
34. Hein DW, Grant DM, Sim E. Update on consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenetics 2000;10:291-292.
35. Zhang H, Singer B. Recursive partitioning in the health sciences. New York: Springer, 1999.
36. Curtis D, North BV, Sham PC. Use of an artificial neural network to detect association between a disease and multiple marker genotypes. Ann Hum Genet 2001;65:95-107.
37. Serretti A, Smeraldi E. Neural network analysis in pharmacogenetics of mood disorders. BMC Med Genet 2004;5:27.
38. Tomita Y, Tomida S, Hasegawa Y, Suzuki Y, et al. Artificial neural network approach for selection of susceptible single nucleotide polymorphisms and construction of prediction model on childhood allergic asthma. BMC Bioinformatics 2004;5:120.
39. Hahn LW, Moore JH. Ideal discrimination of discrete clinical endpoints using multi-locus genotypes. In Silica Biol 2004;4:183-194.
40. Ritchie MD, Hahn LW, Moore JH. Power of multifactor dimensionality reduction for detecting gene-gene interactions in the presence of genotyping error, missing data, phenocopy, and genetic heterogeneity. Genet Epidemiol 2003;24:150-157.
41. Hahn LW, Ritchie MD, Moore JH. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics 2003;19:376-382.
42. Goldstein DB, Tate SK, Sisodiya SM. Pharmacogenetics goes genomic. Nat Rev Genet 2003;4:937-947.
43. Hamdy SI, Hiratsuka M, Narahara K, Endo N, et al. Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population. Br J Clin Pharmacol 2003;55:560-569.
44. Harding RM, Fullerton SM, Griffiths RC, Bond J, et al. Archaic African and Asian lineages in the genetic ancestry of modern humans. Am J Hum Genet 1997;60:772-789.
45. Zietkiewicz E, Yotova V, Jarnik M, Korab-Laskowska M, et al. Genetic structure of the ancestral population of modern humans. J Mol Evol 1998;47:146-155.
46. Harris EE, Hey J. X chromosome evidence for ancient human histories. Proc Natl Acad Sci U S A 1999;96:3320-3324.
47. Kaessmann H, Heissig F, von Haeseler A, Paabo S. DNA sequence variation in a non-coding region of low recombination on the human X chromosome. Nat Genet 1999;22:78-81.
48. Kidd JR, Pakstis AJ, Zhao H, Lu RB, et al. Haplotypes and linkage disequilibrium at the phenylalanine hydroxylase locus, PAH, in a global representation of populations. Am J Hum Genet 2000;66:1882-1899.
49. Tishkoff SA, Pakstis AJ, Stoneking M, Kidd JR, et al. Short tandem-repeat polymorphism/alu haplotype variation at the PLAT locus: implications for modern human origins. Am J Hum Genet 2000;67:901-925.
50. Reich DE, Cargill M, Bolk S, Ireland J, et al. Linkage disequilibrium in the human genome. Nature 2001;411:199-204.
51. Osier MV, Pakstis AJ, Soodyall H, Comas D, et al. A global perspective on genetic variation at the ADH genes reveals unusual patterns of linkage disequilibrium and diversity. Am J Hum Genet 2002;71:84-99.
52. Bouchardy C, Mitrunen K, Wikman H, Husgafvel-Pursiainen K, et al. N-acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk. Pharmacogenetics 1998;8:291-298.
53. Di Luca M, Grossi E, Borroni B, Zimmermann M, et al. Artificial neural networks allow the use of simultaneous measurements of Alzheimer Disease markers for early detection of the disease. J Transl Med 2005;3:30.